Q32 Bio (QTTB) Competitors $1.56 -0.04 (-2.50%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.55 -0.01 (-0.58%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. IFRX, TIL, MCRB, ACOG, CRVO, EPIX, IVVD, IGMS, AVTE, and UNCYShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include InflaRx (IFRX), Instil Bio (TIL), Seres Therapeutics (MCRB), Alpha Cognition (ACOG), CervoMed (CRVO), ESSA Pharma (EPIX), Invivyd (IVVD), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. InflaRx Instil Bio Seres Therapeutics Alpha Cognition CervoMed ESSA Pharma Invivyd IGM Biosciences Aerovate Therapeutics Unicycive Therapeutics Q32 Bio (NASDAQ:QTTB) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do analysts rate QTTB or IFRX? Q32 Bio presently has a consensus price target of $24.71, suggesting a potential upside of 1,484.25%. InflaRx has a consensus price target of $9.33, suggesting a potential upside of 404.50%. Given Q32 Bio's higher possible upside, research analysts clearly believe Q32 Bio is more favorable than InflaRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25InflaRx 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in QTTB or IFRX? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, QTTB or IFRX? Q32 Bio has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Does the media favor QTTB or IFRX? In the previous week, InflaRx had 5 more articles in the media than Q32 Bio. MarketBeat recorded 9 mentions for InflaRx and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.72 beat InflaRx's score of 0.60 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is QTTB or IFRX more profitable? Q32 Bio has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. InflaRx's return on equity of -65.98% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -146.18% -54.49% InflaRx -33,362.70%-65.98%-56.86% Which has stronger valuation and earnings, QTTB or IFRX? InflaRx has higher revenue and earnings than Q32 Bio. InflaRx is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio-$6.65M-2.86-$112.96M-$10.37-0.15InflaRx$165.79K749.12-$46.18M-$0.87-2.13 Does the MarketBeat Community favor QTTB or IFRX? InflaRx received 231 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 65.15% of users gave InflaRx an outperform vote while only 63.16% of users gave Q32 Bio an outperform vote. CompanyUnderperformOutperformQ32 BioOutperform Votes1263.16% Underperform Votes736.84% InflaRxOutperform Votes24365.15% Underperform Votes13034.85% SummaryInflaRx beats Q32 Bio on 13 of the 18 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.03M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.117.3222.5118.54Price / Sales-2.86241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.076.486.734.25Net Income-$112.96M$143.41M$3.22B$248.18M7 Day Performance-15.68%2.30%1.58%1.25%1 Month Performance4.00%7.14%4.05%3.76%1 Year Performance-94.12%-2.61%15.75%5.28% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.6747 of 5 stars$1.56-2.5%$24.71+1,484.2%-94.1%$19.03M$-6,651,000.00-0.1139Upcoming EarningsShort Interest ↓IFRXInflaRx2.5592 of 5 stars$1.22-6.2%$9.00+637.7%+31.2%$81.90M$165,789.00-1.1360Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTILInstil Bio3.3763 of 5 stars$12.44-2.7%$114.00+816.4%+17.6%$81.59MN/A-1.08410Upcoming EarningsPositive NewsHigh Trading VolumeMCRBSeres Therapeutics3.3357 of 5 stars$9.31-7.6%$80.00+759.3%-56.0%$81.17M$126.33M-40.48330Upcoming EarningsAnalyst DowngradeNews CoverageACOGAlpha Cognition2.0491 of 5 stars$5.01-0.6%$20.00+299.2%N/A$80.26MN/A-1.96N/APositive NewsCRVOCervoMed3.5914 of 5 stars$9.15+5.9%$27.50+200.5%-56.3%$79.63M$7.14M-4.514Positive NewsEPIXESSA Pharma3.1599 of 5 stars$1.79+1.1%$9.50+430.7%-73.3%$79.46MN/A-2.5950Positive NewsIVVDInvivyd3.5569 of 5 stars$0.66+1.8%$7.52+1,036.0%-74.9%$79.38M$25.38M-0.34100Upcoming EarningsShort Interest ↓News CoverageGap UpIGMSIGM Biosciences4.3413 of 5 stars$1.30-1.5%$5.50+323.1%-85.9%$77.71M$2.68M-0.36190Upcoming EarningsAVTEAerovate Therapeutics0.4005 of 5 stars$2.68flat$2.25-16.0%-54.4%$77.68MN/A-0.9020Earnings ReportEx-DividendUNCYUnicycive Therapeutics3.7684 of 5 stars$0.65+1.3%$5.50+748.0%-42.7%$77.64M$680,000.00-0.679Short Interest ↓Positive News Related Companies and Tools Related Companies InflaRx Competitors Instil Bio Competitors Seres Therapeutics Competitors Alpha Cognition Competitors CervoMed Competitors ESSA Pharma Competitors Invivyd Competitors IGM Biosciences Competitors Aerovate Therapeutics Competitors Unicycive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QTTB Stock Free QTTB Stock Alerts